Salt-Inducible Kinase 1 Terminates cAMP Signaling by an Evolutionarily Conserved Negative-Feedback Loop in β-Cells

Min Jung Kim, Su Kyung Park, Ji Hyun Lee, Chang Yun Jung, Dong J un Sung, Jae Hyung Park, Young Sil Yoon, Jinyoung Park, Keun Gyu Park, Dae Kyu Song, Hana Cho, Seong Tae Kim, Seung-Hoi Koo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Pancreatic β-cells are critical in the regulation of glucose homeostasis by controlled secretion of insulin in mammals. Activation of protein kinase A by cAMP is shown to be responsible for enhancing this pathway, which is countered by phosphodiesterase (PDE) that converts cAMP to AMP and turns off the signal. Salt-inducible kinases (SIKs) were also known to inhibit cAMP signaling, mostly by promoting inhibitory phosphorylation on CREB-regulated transcription coactivators. Here, we showed that SIK1 regulates insulin secretion in β-cells by modulating PDE4D and cAMP concentrations. Haploinsufficiency of SIK1 led to the improved glucose tolerance due to the increased glucose-stimulated insulin secretion. Depletion of SIK1 promoted higher cAMP concentration and increased insulin secretion from primary islets, suggesting that SIK1 controls insulin secretion through the regulation of cAMP signaling. By using a consensus phosphorylation site of SIK1, we identified PDE4D as a new substrate for this kinase family. In vitro kinase assay as well as mass spectrometry analysis revealed that the predicted Ser(136) and the adjacent Ser(141) of PDE4D are critical in SIK1-mediated phosphorylation. We found that overexpression of either SIK1 or PDE4D in β-cells reduced insulin secretion, while inhibition of PDE4 activity by rolipram or knockdown of PDE4D restored it, showing indeed that SIK1-dependent phosphorylation of PDE4D is critical in reducing cAMP concentration and insulin secretion from β-cells. Taken together, we propose that SIK1 serves as a part of a self-regulatory circuit to modulate insulin secretion from pancreatic β-cells by controlling cAMP concentration through modulation of PDE4D activity.

Original languageEnglish
Pages (from-to)3189-3202
Number of pages14
JournalDiabetes
Volume64
Issue number9
DOIs
Publication statusPublished - 2015 Sep 1

Fingerprint

Phosphotransferases
Salts
Insulin
Phosphorylation
Glucose
Rolipram
Haploinsufficiency
Phosphoric Diester Hydrolases
Adenosine Monophosphate
Cyclic AMP-Dependent Protein Kinases
Mammals
Mass Spectrometry
Homeostasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Salt-Inducible Kinase 1 Terminates cAMP Signaling by an Evolutionarily Conserved Negative-Feedback Loop in β-Cells. / Kim, Min Jung; Park, Su Kyung; Lee, Ji Hyun; Jung, Chang Yun; Sung, Dong J un; Park, Jae Hyung; Yoon, Young Sil; Park, Jinyoung; Park, Keun Gyu; Song, Dae Kyu; Cho, Hana; Kim, Seong Tae; Koo, Seung-Hoi.

In: Diabetes, Vol. 64, No. 9, 01.09.2015, p. 3189-3202.

Research output: Contribution to journalArticle

Kim, MJ, Park, SK, Lee, JH, Jung, CY, Sung, DJU, Park, JH, Yoon, YS, Park, J, Park, KG, Song, DK, Cho, H, Kim, ST & Koo, S-H 2015, 'Salt-Inducible Kinase 1 Terminates cAMP Signaling by an Evolutionarily Conserved Negative-Feedback Loop in β-Cells', Diabetes, vol. 64, no. 9, pp. 3189-3202. https://doi.org/10.2337/db14-1240
Kim, Min Jung ; Park, Su Kyung ; Lee, Ji Hyun ; Jung, Chang Yun ; Sung, Dong J un ; Park, Jae Hyung ; Yoon, Young Sil ; Park, Jinyoung ; Park, Keun Gyu ; Song, Dae Kyu ; Cho, Hana ; Kim, Seong Tae ; Koo, Seung-Hoi. / Salt-Inducible Kinase 1 Terminates cAMP Signaling by an Evolutionarily Conserved Negative-Feedback Loop in β-Cells. In: Diabetes. 2015 ; Vol. 64, No. 9. pp. 3189-3202.
@article{594982d6e9bb4a4083850a2a924da9e7,
title = "Salt-Inducible Kinase 1 Terminates cAMP Signaling by an Evolutionarily Conserved Negative-Feedback Loop in β-Cells",
abstract = "Pancreatic β-cells are critical in the regulation of glucose homeostasis by controlled secretion of insulin in mammals. Activation of protein kinase A by cAMP is shown to be responsible for enhancing this pathway, which is countered by phosphodiesterase (PDE) that converts cAMP to AMP and turns off the signal. Salt-inducible kinases (SIKs) were also known to inhibit cAMP signaling, mostly by promoting inhibitory phosphorylation on CREB-regulated transcription coactivators. Here, we showed that SIK1 regulates insulin secretion in β-cells by modulating PDE4D and cAMP concentrations. Haploinsufficiency of SIK1 led to the improved glucose tolerance due to the increased glucose-stimulated insulin secretion. Depletion of SIK1 promoted higher cAMP concentration and increased insulin secretion from primary islets, suggesting that SIK1 controls insulin secretion through the regulation of cAMP signaling. By using a consensus phosphorylation site of SIK1, we identified PDE4D as a new substrate for this kinase family. In vitro kinase assay as well as mass spectrometry analysis revealed that the predicted Ser(136) and the adjacent Ser(141) of PDE4D are critical in SIK1-mediated phosphorylation. We found that overexpression of either SIK1 or PDE4D in β-cells reduced insulin secretion, while inhibition of PDE4 activity by rolipram or knockdown of PDE4D restored it, showing indeed that SIK1-dependent phosphorylation of PDE4D is critical in reducing cAMP concentration and insulin secretion from β-cells. Taken together, we propose that SIK1 serves as a part of a self-regulatory circuit to modulate insulin secretion from pancreatic β-cells by controlling cAMP concentration through modulation of PDE4D activity.",
author = "Kim, {Min Jung} and Park, {Su Kyung} and Lee, {Ji Hyun} and Jung, {Chang Yun} and Sung, {Dong J un} and Park, {Jae Hyung} and Yoon, {Young Sil} and Jinyoung Park and Park, {Keun Gyu} and Song, {Dae Kyu} and Hana Cho and Kim, {Seong Tae} and Seung-Hoi Koo",
year = "2015",
month = "9",
day = "1",
doi = "10.2337/db14-1240",
language = "English",
volume = "64",
pages = "3189--3202",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Salt-Inducible Kinase 1 Terminates cAMP Signaling by an Evolutionarily Conserved Negative-Feedback Loop in β-Cells

AU - Kim, Min Jung

AU - Park, Su Kyung

AU - Lee, Ji Hyun

AU - Jung, Chang Yun

AU - Sung, Dong J un

AU - Park, Jae Hyung

AU - Yoon, Young Sil

AU - Park, Jinyoung

AU - Park, Keun Gyu

AU - Song, Dae Kyu

AU - Cho, Hana

AU - Kim, Seong Tae

AU - Koo, Seung-Hoi

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Pancreatic β-cells are critical in the regulation of glucose homeostasis by controlled secretion of insulin in mammals. Activation of protein kinase A by cAMP is shown to be responsible for enhancing this pathway, which is countered by phosphodiesterase (PDE) that converts cAMP to AMP and turns off the signal. Salt-inducible kinases (SIKs) were also known to inhibit cAMP signaling, mostly by promoting inhibitory phosphorylation on CREB-regulated transcription coactivators. Here, we showed that SIK1 regulates insulin secretion in β-cells by modulating PDE4D and cAMP concentrations. Haploinsufficiency of SIK1 led to the improved glucose tolerance due to the increased glucose-stimulated insulin secretion. Depletion of SIK1 promoted higher cAMP concentration and increased insulin secretion from primary islets, suggesting that SIK1 controls insulin secretion through the regulation of cAMP signaling. By using a consensus phosphorylation site of SIK1, we identified PDE4D as a new substrate for this kinase family. In vitro kinase assay as well as mass spectrometry analysis revealed that the predicted Ser(136) and the adjacent Ser(141) of PDE4D are critical in SIK1-mediated phosphorylation. We found that overexpression of either SIK1 or PDE4D in β-cells reduced insulin secretion, while inhibition of PDE4 activity by rolipram or knockdown of PDE4D restored it, showing indeed that SIK1-dependent phosphorylation of PDE4D is critical in reducing cAMP concentration and insulin secretion from β-cells. Taken together, we propose that SIK1 serves as a part of a self-regulatory circuit to modulate insulin secretion from pancreatic β-cells by controlling cAMP concentration through modulation of PDE4D activity.

AB - Pancreatic β-cells are critical in the regulation of glucose homeostasis by controlled secretion of insulin in mammals. Activation of protein kinase A by cAMP is shown to be responsible for enhancing this pathway, which is countered by phosphodiesterase (PDE) that converts cAMP to AMP and turns off the signal. Salt-inducible kinases (SIKs) were also known to inhibit cAMP signaling, mostly by promoting inhibitory phosphorylation on CREB-regulated transcription coactivators. Here, we showed that SIK1 regulates insulin secretion in β-cells by modulating PDE4D and cAMP concentrations. Haploinsufficiency of SIK1 led to the improved glucose tolerance due to the increased glucose-stimulated insulin secretion. Depletion of SIK1 promoted higher cAMP concentration and increased insulin secretion from primary islets, suggesting that SIK1 controls insulin secretion through the regulation of cAMP signaling. By using a consensus phosphorylation site of SIK1, we identified PDE4D as a new substrate for this kinase family. In vitro kinase assay as well as mass spectrometry analysis revealed that the predicted Ser(136) and the adjacent Ser(141) of PDE4D are critical in SIK1-mediated phosphorylation. We found that overexpression of either SIK1 or PDE4D in β-cells reduced insulin secretion, while inhibition of PDE4 activity by rolipram or knockdown of PDE4D restored it, showing indeed that SIK1-dependent phosphorylation of PDE4D is critical in reducing cAMP concentration and insulin secretion from β-cells. Taken together, we propose that SIK1 serves as a part of a self-regulatory circuit to modulate insulin secretion from pancreatic β-cells by controlling cAMP concentration through modulation of PDE4D activity.

UR - http://www.scopus.com/inward/record.url?scp=84947320144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947320144&partnerID=8YFLogxK

U2 - 10.2337/db14-1240

DO - 10.2337/db14-1240

M3 - Article

C2 - 25918234

AN - SCOPUS:84947320144

VL - 64

SP - 3189

EP - 3202

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -